Genprex Strengthens Senior Team and Continues to Advance Operations
February 27, 2019
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately. These hirings reflect the company’s latest steps in preparing to grow its operations and place an increased emphasis on corporate communications in 2019.
As the Senior Director of Pharmaceutical Sciences and Manufacturing, Eric Chapdelaine will oversee the company’s analytical development, chemistry, manufacturing and controls, technical operations and supply chain management for Genprex. He brings with him 14 years of experience in the pharmaceutical and biotech industries with a proven track record of driving growth. In his most recent role as the Director of Quality Control and Analytical Development at Cognate BioServices, he oversaw a staff of more than 40 employees in multiple laboratories working on cell and gene therapy. As the Senior Manager of Communications and Marketing, Kalyn Dabbs will be responsible for developing and implementing internal and external communication and marketing plans and managing the company’s digital strategy, an initiative the company has previously indicated will be a corporate focus in 2019. Prior to joining Genprex, Dabbs spent the past six years working in various communications and marketing roles in the healthcare and wellness industries.
“Having Eric and Kalyn join the Genprex team will bring value to the company and enhance our growth and communication efforts,” said Rodney Varner, Genprex’s Chief Executive Officer and Chairman. “Eric’s experience at both biotech companies and contract development and manufacturing organizations will be invaluable in managing and coordinating manufacturing partners and scale-up activities as we expand our research and development efforts and clinical trials of our lead product candidate, Oncoprex™, at the University of Texas MD Anderson Cancer Center and potentially other clinical sites.”
“Kalyn’s role with our company will be essential as we execute our shareholder outreach and communications strategy in the coming year,” Varner continued. “We recognize the importance of boosting awareness of Genprex’s unique approach to cancer treatment, and Kalyn will help enable us to increase the quality and quantity of our corporate communications.”
The new hires are just the latest high-profile additions to the Genprex team in the past few months. Eric and Kalyn join Jan Stephens, RN, who came onto the team at the end of October as Genprex’s Vice President of Clinical Operations to oversee the company’s clinical operations as it expands its clinical trials of Oncoprex.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of GPX-001, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of GPX-001 and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.